Welcome to our dedicated page for SQZ news (Ticker: SQZ), a resource for investors and traders seeking the latest updates and insights on SQZ stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect SQZ's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of SQZ's position in the market.
SQZ Biotechnologies (NYSE: SQZ) presented preclinical data on its novel SQZ Antigen Presenting Cells (APCs) and SQZ Activating Antigen Carriers (AACs) at SITC 2020. The data showcased robust CD8 T cell activation and promising anti-tumor responses in murine models. Key findings include enhanced anti-tumor activity with SQZ-PBMC-HPV combined with PD-1 checkpoint inhibitors. Furthermore, the company is conducting a Phase 1 trial evaluating SQZ-PBMC-HPV in conjunction with Atezolizumab for HPV16+ advanced tumors, highlighting rapid manufacturing capabilities and strong immunological responses.
SQZ Biotechnologies Company (NYSE: SQZ) has priced its initial public offering (IPO) at $16.00 per share, offering 4,411,765 shares. The underwriters have a 30-day option to purchase an additional 661,764 shares. Trading is expected to commence on October 30, 2020, with the offering closing on November 3, 2020, pending customary conditions. BofA Securities, Evercore ISI, and Stifel are the joint book-running managers for this offering. The Securities and Exchange Commission declared the registration effective on October 29, 2020.